Neurocrine Biosciences (NBIX) has disclosed a new risk, in the Innovation / R&D category.
Neurocrine Biosciences faces significant risk with the launch of CRENESSITY due to potential challenges in market adoption by both patients and physicians. Despite FDA approval and a dedicated commercial team, the success of CRENESSITY hinges on its acceptance as a treatment for classic CAH, which may be hindered by inadequate reimbursement and the requirement for extensive education efforts. Any negative publicity or regulatory setbacks could further impede its market potential, potentially affecting the company’s stock price and overall business health. Failure to achieve anticipated sales levels could result in adverse financial consequences for Neurocrine Biosciences.
The average NBIX stock price target is $166.50, implying 42.49% upside potential.
To learn more about Neurocrine Biosciences’ risk factors, click here.